The process of protein ubiquitination is a central tenet of the ubiquitin proteasome system (UPS) and is crucial in many fundamental cellular processes such as proteolysis, cell-cycle control, DNA repair and apoptosis. 1, 2 The importance of this pathway in controlling such key cellular processes cannot be understated and increasing evidence linking the UPS to human diseases such as cancer 3 and neurodegenerative disorders 4 is emerging. The approved proteasome inhibitor Velcade ® (bortezimib) has demonstrated that the UPS is a viable target for small molecule therapeutic intervention. 5 Targeting the UPS upstream of the proteasome may therefore yield new opportunities for targeted therapeutics with improved specificity and toxicity profiles.
Ubiquitination is a post-translational modification via covalent attachment of the 76 amino acid protein ubiquitin to lysine side chains of target substrates. This elegant and complex molecular "tagging" of target proteins is effected by E1 (activating), E2 (conjugating) and E3 (ligase) enzymes and has multiple functions including targeted substrate degradation, activation for further processing and cellular localization. 6 The process of ubiquitination is reversed by deubiquitinase enzymes (DUBs) of which there are around 100 encoded by human genes. 7 Ubiquitin specific proteases (USPs) are cysteine proteases that comprise the largest (>50) sub-class of DUBs and are gaining interest as an emerging target class for pharmaceutical intervention. 8 There are sparingly few validated small molecule inhibitors reported for USPs and as such there is an acute need to develop robust probe compounds for use in deciphering the biological pathways associated with the USP target class.
USP7 represents one of the most studied USPs from a target class that remains largely underexplored and as such has gained attention in recent years due to its association with cancer. 9, 10 USP7 is involved in the regulation of the stability of the tumor suppressor p53 via deubiquitination of the oncoprotein Mdm2. 11 USP7 mediated stabilization of Mdm2 reduces cellular p53 and may protect damaged cells from apoptosis. In addition, USP7 has also been implicated in the regulation of several other key signaling proteins linked to tumorigenesis. [12] [13] [14] [15] [16] [17] Targeting USP7 with small molecules has therefore been of great interest over recent years but has until recently met with limited success due to several factors including poor compound specificity, low potency and/or poor compound properties. 18 Very recent publications have described the characterization of more drug-like USP7 inhibitors that further reinforce the potential druggability of this target class. [19] [20] [21] [22] Recently we published the detailed in vitro biological profiling and co-crystal structures of highly potent non-covalent USP7 inhibitors in a variety of biochemical and cellular assays. 22 These compounds have proven to be highly valuable tools for interrogating the complex biology of USP7 and will enable further studies aimed at delineating USP7 biology. Herein we describe the hit-finding and medicinal chemistry efforts towards these tool compounds, summarize the SAR and outline the identification of a novel sub-series of USP7 inhibitors. The binding mode (by way of X-ray co-crystallography) of this sub-series is highlighted as is the pharmacokinetic profiling of early leads from both series.
Our USP7 hit-finding strategy involved initial fragment screening using surface plasmon resonance (SPR) coupled with the parallel in vitro benchmarking of published USP7 inhibitors. Briefly, SPR screening of 1.9k fragments versus immobilized USP7 catalytic domain afforded a range of primary USP7 binding fragments including thieno-pyrimidinone 1 (Figure 1) . Compound 1 was found to be a high ligand efficiency USP7 binder (LE = 0.47) with an SPR equilibrium binding constant (KD) of 471 µM (Figure S1 , SI). Binding of compound 1 to USP7 was subsequently confirmed by orthogonal techniques (ligand observed STD, CPMG and WaterLOGSY NMR experiments) (Figure S2 , SI). Further profiling revealed that 1 had excellent aqueous kinetic solubility (>200 µM) and was free from redox cycling activity -a liability that has the potential to lead to false positive readouts in biochemical assays. 1 and analogues thereof were then incorporated into our wider USP7 medicinal chemistry program which involved scaffold-hopping as well as hybridization with known literature USP binding motifs (e.g. 4-hydroxypiperidines 23 ). From this program of work compounds 2 and 3 were synthesized and found to have modest USP7 biochemical activity ( Table 1) . Compounds 2 and 3 were deemed suitable for further SAR studies due to their reasonable ligand efficiencies (LE) and favorable physicochemical properties. A range of analogues derived by scaffold-hopping to other fused 5-membered ring pyrimidinones were explored in parallel to substitution on the bicyclic pyrimidinone core ( Table 2) . Furano, pyrazolo and thiazolo-pyrimidinone analogues 4-8 were largely equipotent with thieno-pyrimidinones 2 and 3. Substitution of a lipophilic bromine atom at either the C-5 or C-6 positions of the thiophene ring in compounds 9 and 10 did not lead to marked USP7 potency gains whereas substitution at the C-7 position led to an appreciable (ca. 5-fold) potency enhancement as demonstrated by compound 11. Pleasingly, substitution at this position with other lipophilic groups such as cyclopropyl 12, alkynyl 13 and phenyl 14 also afforded noticeable potency gains versus the non-substituted analogue 3. Substitution at the 2-position of the pyrimidinone ring with a methyl substituent was not tolerated (compound 15). Table 2 With potency gains of ca. 5-10 fold attainable via modification of the bicyclic thienopyrimidinone ring, our attention turned to SAR analysis of the phenethylamide moiety. During the course of our studies a key breakthrough was the observation that methyl substitution at the benzylic position of compounds such as 11 led to a significant (>40-fold) increase in USP7 potency. This large increase in potency was fully dependent on the stereochemistry of the newly installed chiral methyl group as exemplified by compounds 16 and ent-16 (Figure 2 ). Interestingly, the (R)-enantiomer 16 was found to be >150 times more potent than the corresponding (S)-enantiomer ent-16. With potent USP7 compounds such as 16 now in hand we initiated co-crystallization studies with the catalytic domain (amino acids 207-560) of USP7. We subsequently obtained a 2.3 Å resolution X-ray co-crystal structure of compound 16 and USP7 that revealed the ligand bound in the catalytic cleft between the β-sheet of the palm subdomain and the helices of the thumb subdomain. 22 Removal of key ligand hydrogen-bonding heteroatoms (such as the amide carbonyl, tertiary alcohol or pyrimidinone N-1 nitrogen from the bicyclic core) was highly deleterious to USP7 binding (data not shown) highlighting the importance of each individual interaction.
Aided by the X-ray co-crystal structure, we were able to use structure-based design to further optimize our USP7 inhibitors with the aim of enhancing target affinity (whilst retaining favorable physicochemical properties). Our initial focus centered on the thiophene ring of compound 16 which contains a bromine substituent at C-7 that is orientated towards the protein surface with a high degree of solvent exposure and was thus viewed as a promising vector for new analogue design and optimization. Encouragingly, scaffold-hopping from the thienopyrimidinone core of compound 16 to the more drug-like Nmethyl pyrazolo-pyrimidine core (compound 17, Table 3 ) not only lowered overall lipohilicity (logD7.4 1.5 vs 2.3) but was also not detrimental to USP7 activity. Given this result, we decided to concentrate our efforts on the pyrazolo-pyrimidinone core and a summary of the SAR is presented in Table 3 . Table 3 . USP7 biochemical potencies of N-methyl pyrazolo-pyrimidinones.
Our strategy (guided by docking studies using the co-crystal structure) was centered on targeting both hydrogen-bond and hydrophobic interactions via selective substitution at the pyrazole C-3 position. Incorporation of alkynyl, alkenyl or isopropyl substituents at the C-3 position (compounds 18-21) did not prove fruitful, however, when pyrazole or phenyl groups were incorporated at this position a ca. 10-fold increase in USP7 potency was observed (e.g. compound 23, IC50 0.03 µM). This marked increase in potency may involve a CH-π interaction between the pendant pyrazole or phenyl groups of 22 or 23 and Gln351 as postulated in the published co-crystal structure. 22 Addition of an ortho-fluoro group to the pendant phenyl in compound 23 led to a slight decrease in potency (compound 24, IC50 0.09 µM) in contrast to ortho-anilino substituted compound 25 which was around 40-fold less potent than 23 -possibly due to the larger ortho-NH2 substituent increasing the dihedral angle between the phenyl ring and the core, causing an unfavorable steric clash between the phenyl ring and the protein surface. Addition of hydrogen-bond acceptors and donors at the meta and para positions on the pendant phenyl group (compounds 26-30) largely maintained potency in relation to 23 with the exception of compound 31 which showed a marked decrease in potency, most likely due to the added steric bulk of the morpholine group. Interestingly, the para-carboxamide or benzylic alcohol groups in compounds 32 and 33 did not lead to potency increases whereas the para-benzylic amine moiety in compound 34 (IC50 = 6 nM) provided a ca. 5-fold increase in potency over compound 23. The (S)-Me enantiomer of 34 was found to have an IC50 of 2.4 µM, representing a 400-fold decrease in USP7 potency. 22 In addition to identifying the promising pyrazolo-pyrimidinones described above, we also investigated how truncation of the bicyclic core would affect USP7 binding. Hence, a series of monocyclic pyrimidinones such as compound 35 were synthesized ( Table 4 ). Although only moderately active, compound 35 (IC50 = 23 µM) represented a promising and ligand efficient (LE = 0.25) starting point for further analogue work with respect to its low molecular weight and logD7.4 (355 and 0.9 respectively). A range of analogues were subsequently prepared substituted at the C-6 position of the pyrimidinone ring with representative examples shown in Table 4 . Overall SAR at this position suggested that substitution was largely beneficial for USP7 potency. Substitution with simple amines such as methylamine or aniline (compounds 36 and 37) increased potency by 5 to 10-fold versus the unsubstituted analogue 35. Switching the -NH linker in compound 37 to -CH2 in compound 38 resulted in a significant USP7 potency dropoff (IC50 = 1.9 µM versus 90 µM). Potency was regained when the methylene phenyl linker in compound 38 was switched to an alkynyl linker group (compound 39, IC50 = 2.8 µM). Ethylenediamine analogue 40 (IC50 = 0.12 µM) represented a >190-fold improvement in USP7 biochemical potency over the simple analogue 35 suggestive of new hydrogen-bonding interactions. Indeed, close analogues of compound 40 in which the hydrogen-bonding interaction potential of the ethylenediamine side-chain was modified led to decreases in potency (compounds 41-45). Pyrrolidine analogue 46 represented the first 0.006 sub-100 nM compound from this series and suggested that the basic pyrrolidine nitrogen was making a critical hydrogen-bond with USP7. Intrigued by the observed SAR in which the precise nature of the side-chain linker and the pKa of the amine both seemed crucial, molecular modelling suggested that a close interaction between the protonated amine of 46 and Asp295 was potentially achievable. This was subsequently confirmed via a high resolution (2.2 Å) X-ray co-crystal structure of compound 46 bound to USP7 that demonstrates a similar binding mode to that of compound 16 reported previously (Figures 3A and 3B ). 22 Figure 3 . A. High-resolution X-ray co-crystal structure of USP7 in complex with 46 (PDB code: 6F5H). B. Overlay of compounds 46 (green) and 16 22 (orange, PDB code: 5N9R) bound to USP7.
In addition to the important hydrogen bond interaction network observed previously with 16, we also observed the postulated additional hydrogen bond between the protonated nitrogen of the pyrrolidine side-chain of 46 and Asp295 demonstrating a unique bidentate binding interaction pattern with Asp295 which had not been previously reported. This extra interaction appears to be crucial for improving affinity within the monocyclic series. As with compound 16, the amide carbonyl in 46 interacts with the Tyr465 hydroxyl group and the ligand tertiary alcohol and forms hydrogen bonds with both Asp295 and Val296. With regards to the pyrimidinone ring of 46, the carbonyl oxygen atom forms a hydrogen bond with the backbone NH of Phe409 whereas the N-4 ring atom forms a hydrogen bond with Gln297 effectively stabilizing the monocyclic ring with interactions above and below the ring system ( Figure 3A) . The folded bioactive conformation of the phenethylamide side chain of 46 may partly be induced by allylic 1,3-strain between the benzylic CH and the phenyl ring as well as stabilization via a CH-π intramolecular interaction between the piperidine C-3 axial hydrogen and the phenyl ring. These intramolecular conformational drivers may in part be responsible for inducing binding site side-chain movements that create the overall binding pocket that accommodates this portion of the ligand. The resulting conformation is stabilized by a cation-π interaction between Lys420 and the ligand phenyl ring in addition to an edge-toface π-π interaction with Phe409. Additional contacts between the phenethylamide methylene hydrogen atoms of 46 and the π system of His461 may also contribute to overall binding efficiency.
With highly potent USP7 inhibitors (from two distinct subseries) such as 34 and 46 in hand, we performed extensive in vitro profiling and demonstrated that 34 shows potent target engagement of endogenous USP7 in cells as well as excellent selectivity for USP7 in panels of deubiquitinases, proteases and kinases. 22 In addition, we also identified cancer cell lines that are hyper-sensitive to our USP7 inhibitors. Similar to compound 34, monocyclic analogue 46 shows excellent selectivity versus a panel of USPs (n = 21) when screened at a fixed concentration of 10 µM as well as potent intracellular USP7 target engagement (EC50 = 0.32 µM) in cells (Figures 4A and 4B) . In parallel to the in-depth cellular profiling outlined above, potent compounds were assessed in a range of in vitro assays in order to determine their suitability for in vivo studies. Generally, non-basic analogues were unstable in both human and mouse liver microsomes and had poor caco-2 permeability if they contained >1 hydrogen bond donor (HBD), thus precluding them from in vivo PK studies (e.g. compounds 23 and 33, Table 5 ). Likewise, benzylic amine 34 was found to have high in vitro metabolic turnover in both human and mouse liver microsomes (with predicted hepatic clearances of 18 mL/min/kg and 62 mL/min/kg respectively), whereas monocycle 46 had moderate metabolic stability in human and mouse liver microsomes (11 mL/min/kg and 34 mL/min/kg respectively). The aqueous kinetic solubility of both 34 and 46 was high (KSol > 190 µM) but the caco-2 A:B permeability of each at pH 6.5 was found to be low (Papp < 0.3 x 10 -6 cm/s) limiting their potential for oral dosing. The low predicted in vivo hepatic stability of the highly potent benzylic amine 34 encouraged us to carry out further chemical optimization in order to identify compounds with improved metabolic stability to facilitate in vivo proof-ofconcept studies. As part of the chemistry program aimed at improving metabolic stability of compound 34, trifluoromethyl analogue 47 (Figure S3 , SI) was prepared via an asymmetric hydrogenation route described previously. 22 Compound 47 was found to have improved in vitro microsomal stability in both human and mouse microsomes compared to compound 34 (HLM CLhep 7 mL/min/kg vs 18 mL/min/kg and MLM CLhep 28 mL/min/kg vs. 62 mL/min/kg) ( Table 5 ). Furthermore, 47 largely maintained USP7 biochemical potency when contrasted with methyl analogue 34 (IC50 = 22 nM vs 6 nM).
The pharmacokinetic profiles of compounds 46 and 47 were subsequently assessed in male CD-1 mice ( Table 6 ). As expected from their low caco-2 permeabilities (A:B Papp < 0.3 x 10 -6 cm/s) both compounds exhibited poor oral bioavailability (F < 1%). However, when dosed intraperitoneally (i.p.) both compounds exhibited reasonable bioavailability (F = 44% and 64% for 46 and 47 respectively). Volume of distribution for each compound was low (Vss ≤ 1 L/kg), in line with their low lipophilicities (logD7.4 ≤ 0). Compound 46 demonstrated low plasma clearance (CL = 13 mL/min/kg) whereas compound 47 had moderate clearance (CL = 32 mL/min/kg). Further optimization studies aimed at improving PK profiles based on these encouraging preliminary in vivo results are underway and will be reported in due course. In conclusion, we have identified and optimized highly potent USP7 inhibitors based on two different core chemotypes. Key compounds have a well understood mode of binding as evidenced by the high resolution co-crystal structures obtained. These USP7 inhibitors have been highly valuable in validating the druggability of USP7 as well as enabling studies towards a deeper understanding of the underlying biology of USP7 and its potential as a therapeutic target. Efforts are continuing towards the further development of these inhibitors into compounds suitable for in vivo proof-of-concept studies.
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Materials and reagents:
Common organic solvents that were used in reactions (e.g. THF, DMF, DCM, and methanol) were purchased anhydrous from Sigma-Aldrich ® in Sure/Seal TM bottles and were handled appropriately under nitrogen. Water was deionised using an Elga PURELAB Option-Q. All other solvents used (i.e. for work-up procedures and purification) were generally HPLC grade and were used as supplied from various commercial sources. Unless otherwise stated, all starting materials used were purchased from commercial suppliers and used as supplied.
For assay purposes, all reagents and chemicals were purchased from Sigma-Aldrich ® unless otherwise stated. All inhibitors were prepared as 10 mM DMSO stocks for cell culture experiments and stored in a controlled environment using the MultiPod system. CellTiter-Glo ® was purchased from Promega (#G7571). The ubiquitin-propargylamine (Ub-PA) probe was purchased from UbiQ (#UbiQ-057). Unless otherwise stated, all other reagents were obtained from commercial sources and used without further purification. 
Experimental Procedures and Spectroscopic Data:

General Experimental Conditions
Microwave synthesis
Microwave experiments were carried out using a Biotage Initiator™ Eight system or a CEM Discover™/Explorer24™ system controlled by Synergy 1.5 software. Both machines give good reproducibility and control at temperature ranges from 60-250 °C and pressures of up to a maximum of 20 bar.
Flash chromatography
Purification of compounds by flash chromatography was achieved using a Biotage Isolera Four system. Unless otherwise stated, Biotage KP-Sil SNAP cartridge columns (10-340 g) were used along with the stated solvent system and an appropriate solvent gradient depending on compound polarity. In the case of more polar and basic compounds, Biotage KP-NH SNAP cartridge columns (11 g) were used. 1 H NMR spectra were recorded at ambient temperature using a Bruker Avance (300 MHz), Bruker Avance III (400 MHz) or Bruker Ascend (500 MHz) spectrometer. All chemical shifts (δ) are expressed in ppm. Residual solvent signals were used as an internal standard and the characteristic solvent peaks were corrected to the reference data outlined in J. Org. Chem., 1997, 62, p7512-7515; in other cases, NMR solvents contained tetramethylsilane, which was used as an internal standard.
NMR spectroscopy
Liquid Chromatography Mass Spectrometry (LCMS)
Liquid Chromatography Mass Spectrometry (LCMS) experiments to determine retention times (R T ) and associated mass ions were performed using the following method:
Method A: The system consisted of an Agilent Technologies 6130 quadrupole mass spectrometer linked to an Agilent Technologies 1290 Infinity LC system with UV diode array detector and autosampler. The spectrometer consisted of an electrospray ionization source operating in positive and negative ion mode. LCMS experiments were performed on each sample submitted using the following conditions: LC Column: Agilent Eclipse Plus C18 RRHD, 1. 
Preparative High Pressure Liquid Chromatography
Method A: This system consisted of an Agilent Technologies 6120 single quadrupole mass spectrometer linked to an Agilent Technologies 1200 Preparative LC system with multiple wavelength detector and autosampler. The mass spectrometer used a multimode ionization source (electrospray and atmospheric pressure chemical ionizations) operating in positive and negative ion mode. Fraction collection was mass-triggered (multimode positive and negative ion). Purification experiments, unless otherwise stated, were performed under basic conditions at an appropriate solvent gradient that was typically determined by the retention time found using the LCMS method. In cases where the basic conditions were unsuccessful, acidic conditions were employed.
Basic conditions: LC Column: Waters XBridge™ Prep C18 5 μm OBDTM 19 x 50 mm column at rt. Mobile phase: A) 0.1% (v/v) ammonium hydroxide in water; B) 0.1% (v/v) ammonium hydroxide in 95:5, acetonitrile/water. Total experiment time was ca. 10 min and an example method is given: Method B: This system consisted of a Waters Autopurification HPLC/MS, with a Gemini NX-C18 column from Phenomenex, 5 µm, 50 mm x 30 mm i.d., running at a flow rate of 60 mL/min, 25 °C with UV diode array detection (210-400 nm) and mass-directed collection. A typical gradient was 5-50% HPLC grade acetonitrile (mobile phase B) in HPLC grade water + 0.1% (v/v) ammonia solution (mobile phase A) over 10 min, or modified as necessary. The mass spectrometer used was a Waters Micromass ZQ2000 spectrometer, operating in positive or negative ion electrospray ionisation modes, with a molecular weight scan range of 150 to 1000.
The pure fractions were combined and concentrated using a Genevac EZ-2 Elite, unless stated otherwise.
Final compound purity analysis
The purity of final compounds was assessed by LCMS and 1 H NMR. The HPLC purity of each compound was measured using the method stated compared to a blank.
High Resolution Mass Spec
High resolution mass spectra were acquired on a Thermo ScientificLTQ Orbitrap XL spectrometer at the EPSRC UK National Mass Spectrometry Facility (University of Swansea).
General procedures
General procedure 1: Epoxide opening with a pyrimidinone A suspension of the pyrimidinone (1 equiv.), epoxide (1-3 equiv.) and Cs 2 CO 3 (1-3 equiv.) in DMF were heated at 80 °C for 10-24 h. The reaction was allowed to cool to rt, saturated NH 4 Cl (aq) was added and the resulting mixture was extracted with DCM (x3) using a Biotage phase separator. The combined organic phases were concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product.
General procedure 2: N-Boc deprotection
A solution of the N-Boc piperidine in DCM/TFA was stirred for 1-24 h at rt before being concentrated under reduced pressure. The residue was then dissolved in triethylamine and DCM before being purified by flash chromatography 4 (Biotage KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc or 0-100% DCM in cyclohexane or PE, then 0-30% MeOH in DCM) to give the product.
General procedure 3: EDC coupling
A solution of amine (1 equiv.), carboxylic acid (1 equiv.) and EDC (3 equiv.) was stirred in (DCM) for 1-24 h at rt. The reaction was quenched by the addition of water and the resulting mixture was extracted with DCM (x3) using a Biotage phase separator. The combined organic phases were concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product.
General procedure 4: HATU coupling in DCM
To a suspension of the amine (1 equiv.), carboxylic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DCM was added DIPEA (1-4 equiv.). The reaction was stirred for 1-24 h at rt before being quenched by the addition of saturated Na-HCO3(aq) and the resulting mixture was extracted with DCM (x3) using a Biotage phase separator. The combined organic phases were concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product.
General procedure 5: Suzuki-Miyaura coupling
A reaction vial was charged with a mixture of the bromide (1 equiv.), the organoboron reagent (1-3 equiv.), a Pd catalyst (0.05-0.1 equiv.) and an inorganic base (2-5 equiv.) in 1,4-dioxane/water and the O 2 was removed by evacuating and refilling with N 2 three times or by bubbling N 2 through the mixture before the reaction tube was sealed. The reaction was heated under the indicated conditions for the indicated time before being cooled to rt and saturated NH 4 Cl (aq) added. The resulting mixture was extracted with DCM (x3) using a Biotage phase separator. The combined organic phases were concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and/or KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product.
General procedure 6: Sonagashira coupling
A reaction tube was charged with the bromide (1 equiv.), a Cu catalyst (0.2-0.4 equiv.) and a Pd catalyst (0.1-0.2 equiv.) and then evacuated and refilled with N 2 three times. To this was added toluene, triethylamine (20-40 equiv.) and the alkyne (1-4 equiv.) before the mixture was again evacuated and refilled with N 2 three times. The reaction tube was sealed and the reaction was heated under the indicated conditions for the indicated time. The reaction was cooled to rt and quenched by the addition of saturated NH 4 Cl (aq) . The mixture was extracted with DCM (x 3) using a Biotage phase separator, the combined organic phases were concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product. Step 1: 5-Bromothieno[2,3-d]pyrimidin-4(3H)-one: To a stirred suspension of thieno[2,3-d]pyrimidin-4(3H)-one (250 mg, 1.64 mmol) in acetic acid (1.6 mL) in a reaction tube was dropwise added Br 2 (0.254 mL, 4.93 mmol). The reaction tube was sealed and the mixture was heated at 95 °C for 16 h before the reaction was allowed to cool to rt. To this mixture was added MeOH (7 mL) and Et 2 O (7 mL). The resulting precipitate was collected by filtration and washed with Et 2 O (50 mL) before being dried under high vacuum to give the title compound (352 mg, 93%) as a beige solid. 6-((4-hydroxypiperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d ]pyrimidin-7one: General procedure 2 using tert-butyl 4-hydroxy-4-((2-methyl-7-oxo-3-((trimethylsilyl)ethynyl)-2,7-dihydro-6H-pyrazolo [4,3-d] pyrimidin-6-yl)methyl)piperidine-1-carboxylate (32 mg, 69.6 µmol), TFA (1 mL) and DCM (1 mL) gave a mixture of the TMS and desilated alkyne. This material was treated with K 2 CO 3 (29 mg, 0.209 mmol) in MeOH (1 mL) for 45 min before the reaction mixture was purified directly by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% DCM in PE then 0-40% MeOH in DCM) affording the title compound (16 mg, 79%) as a colourless solid. LCMS (Method A, ES + ): R T = 0.33 min, m/z Calcd for C 14 H 18 N 5 O 2 [M+H] + 288, found 288. 6-((4-hydroxy-1-(3-phenylbutanoyl) Step 1: (R)-3-(3-(Aminomethyl)phenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d 
LCMS (Method
Compound 12: 7-Cyclopropyl-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-one
Compound 13: 7-Ethynyl-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-one
Step 3: 7-Ethynyl-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)one:
Compound 14: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-7-phenylthieno[3,2-d]pyrimidin-4(3H)-one
Compound 15: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-2-methylthieno[3,2-d]pyrimidin-4(3H)-one
Compound 18: (R)-3-Ethynyl-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Step 2: 3-Ethynyl-
Step 3: (R)-3-Ethynyl-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one:
Compound 19: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-3-(3-hydroxy-3-methylbut-1yn-1-yl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Compound 20: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-(prop-1-en-2-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Compound 21: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-3-isopropyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Compound 22: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-(1H-pyrazol-5-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Compound 23: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-phenyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Compound 24: (R)-3-(2-Fluorophenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Compound 27: (R)-3-(3-Aminophenyl)-
Compound 29: (R)-3-(6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-3-yl)benzamide
Step 1: (R)-3-Phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)butan-1-one:
To a solution of trimethylsulfonium iodide (6.09 g, 29.9 mmol) in DMSO (30 mL) was added NaH (1.19 g, 29.9 mmol). The resulting mixture was stirred at rt for 1 h before a solution of (R)-1-(3-phenylbutanoyl)piperidin-4-one (2.93 g, 11.9 mmol) in DMSO (15 mL) was added. The reaction mixture was stirred at 50 °C for 2 h before it was allowed to cool to rt, quenched by the addition of water (100 mL) and the resulting mixture was extracted with Et 2 O (3 x 50 mL). The combined organic phases were washed with brine (50 mL), dried over Na 2 SO 4 , concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil 50 g cartridge, 0-70% EtOAc in PE) to give the title compound 
Step 2: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(methylamino)pyrimidin-4(3H)-one:
A solution of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (30 mg, 76.9 µmol) in 2 M MeNH 2 in THF (0.5 mL, 1.00 mmol) was heated at 130 °C under microwave irradiation for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (23 mg, 77%) as a colourless solid. LCMS (Method A, ES + ): R T = 0.84 min (purity >96% at 254 nm), m/z Calcd for C 21 Hydroxy-1-(3-phenylbutanoyl) Step 1: tert-Butyl 4-((4-chloro-6-oxopyrimidin-1(6H)-yl)methyl)-4-hydroxypiperidine-1-carboxylate: A solution of 6-chloropyrimidin-4(3H)-one (3.72 g, 28.5 mmol), tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate 1 (6.08 g, 28.5 mmol) and DIPEA (7.47 mL, 42.7 mmol) in DMF (35 mL) was heated at 80 °C for 16 h. The reaction mixture was allowed to cool to rt before it was quenched by the addition of saturated NH 4 Cl (aq) (100 mL) and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over MgSO 4 , concentrated under reduced pressure and the residue was purified by flash chromatography (GraceResolv silica 120 g cartridge, 0-100% EtOAc in cyclohexane) to give the title compound Step 2: 6-Benzyl-3-((4-hydroxypiperidin-4-yl)methyl)pyrimidin-4(3H)-one: A solution of tert-butyl 4-((4-chloro-6-oxopyrimidin-1(6H)-yl)methyl)-4-hydroxypiperidine-1-carboxylate (60 mg, 0.174 mmol), potassium benzyltrifluoroborate (38 mg, 0.192 mmol) and triethylamine (36 µL, 0.26 mmol) in toluene (2 mL) and water (0.2 mL) was purged with N 2 before PdCl 2 (dppf) (12.8 mg, 17.4 µmol) was added. The reaction tube was sealed and the mixture was heated at 110 °C for 16 h. The reaction was allowed to cool to rt, diluted with water (20 mL) and extracted into EtOAc (3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over MgSO 4 and concentrated under reduced pressure. The residue was purified by flash chromatography (GraceResolv silica 12 g cartridge; 10-100% EtOAc in cyclohexane, then 0-15% MeOH in EtOAc) to give a colourless glass. This was dissolved in DCM (1 mL) and TFA (1 mL) and stirred for 10 min before being concentrated under reduce pressure. The residue was dissolved in methanol and added to a 2 g SCX-2 cartridge. The column was flushed with MeOH before being eluted with 2 M NH 3 in MeOH. The NH 3 fractions were concentrated under reduced pressure to give the title compound (11 mg, 21%) as a colourless glass. LCMS (Method A, ES + ): R T = 0.55 min, m/z Calcd for C 17 H 22 N 3 O 2 [M+H] + 300, found 300.
Compound 37: (R)-3-((4-
Step 3: (R)-6-Benzyl-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one:
General procedure 4 using 6-benzyl-3-((4-hydroxypiperidin-4-yl)methyl)pyrimidin-4(3H)-one ( Hydroxy-1-(3-phenylbutanoyl) 3-((4-Hydroxypiperidin-4-yl) methyl)-6-(phenylethynyl)pyrimidin-4(3H)-one: A solution of tert-butyl 4-((4-chloro-6-oxopyrimidin-1(6H)-yl)methyl)-4-hydroxypiperidine-1-carboxylate (100 mg, 0.291 mmol), phenylacetylene (70 µL, 0.640 mmol) and trimethylamine (0.24 mL, 1.75 mmol) in DMF (1 mL) was purged with N 2 before AuCl(PPh 3 ) (7.2 mg, 14.5 µmol) and PdCl 2 (PPh 3 ) 2 (10.2 mg, 14.5 µmol) were added. The reaction tube was sealed and the reaction was heated at 60 °C for 16 h before being allowed to cool to rt. The mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over MgSO 4 and concentrated under reduced pressure. The residue was purified by flash chromatography (GraceResolv 12 g cartridge, 0-100% EtOAc in cyclohexane) to give an orange syrup. This was dissolved in DCM (1 mL) and TFA (1 mL) and stirred for 5 min before being concentrated under reduced pressure. The residue was dissolved in MeOH and added to a 2 g SCX-2 cartridge. The column was flushed with MeOH before being eluted with 2 M NH 3 
Compound 39: (R)-3-((4-
